John Muir Health
Print this page
Email this page to a friend

New Studies Now Open
Study Updates
Links

New Studies Now Open

CALGB 70305: A randomized study to prevent Lymphedema in women treated for breast cancer

NSABP B-42: A clinical trial to determine the efficacy of five years of Letrozole compared to placebo in patients completing five years of hormonal therapy consisting of an aromastase inhibitor (AI) or Tamoxifen followed by an AI in prolonged disease-free survival in postmenopausal women with hormone receptor positive breast cancer.

Study Updates

Initial Results of the Study of Tamoxifen and Raloxifene (STAR) Released: Osteoporosis Drug Raloxifene Shown to be as Effective as Tamoxifen in Preventing Invasive Breast Cancer.

In STAR, both drugs reduced the risk of developing invasive breast cancer by about 50 percent. In addition, within the study, women who were prospectively and randomly assigned to take raloxifene daily, and who were followed for an average of about four years, had 36 percent fewer uterine cancers and 29 percent fewer blood clots than the women who were assigned to take tamoxifen.

For you convenience, links to related information regarding Clinical Trials and Research:

Clinical Trial Links

www.centerwatch.com
www.clinicaltrials.gov
www.cancertrials.com
www.breastcancertrials.org

Research Links

National Cancer Institute
National Institutes of Health
Health and Human Services
Food & Drug Administration

[back to top]